Dr Menon might as well have been retired for awhile now.
Dr Menon tweaked the dosing for Brilacidin ph2b ABSSSI trial. He suggested lowering the dosage from what the PolyMedix trials had been using. And, as you like to say, Brilacidin ABSSSI has been sitting on hold for awhile now.
His Kevetrin work has long since been done. The reformulation work on Kevetrin appears to have been farmed out. If not, why was it stopped due to the expense? It appears to me that Dr Menon hasn't been working on that.
I'm glad he's still on the board of directors of the company he cofounded.
It will be interesting to see how this is perceived by the market on Monday. And, it's curious that it wasn't in the corporate update.
Since he has been hated on so much online, some may think this is good news.
Those that think he's continued to be active in his research may think it's bad news.
In Reply to 'scottsmith'
He allegedly tweaked the formula.
News 
Market Data 
Discover 
